Search

Changes to Formulary as of 18th November 2020:

BNF Category Number

Product/indication

Detail of change

4

 

Added link to NICE NG59

5

 

Added link to NICE NG182

8.15

Pembrolizumab

Added link to NICE TA650

8.1.5

Polatuzumab vedotin

Added as RED drug and added link to NICE TA649

3.4.2

Dupilumab

Added as NOT APPROVED drug and added link to NICE TA648

9.1.3

Eculizumab

Added link to NICE TA647

8.1.5

Glasdegib

Added as NOT APPROVED drug and added link to NICE TA646

8.1.5

Avelumab

Added as RED drug and added link to NICE TA645

8.1.5

Entrectinib

Added link to NICE TA644

8.1.5

Entrectinib

Added as RED drug and added link to NICE TA643

8.1.5

Gilteritinib

Added as RED drug and added link to NICE TA642

8.1.5

Brentuximab vedotin

Added link to NICE TA641

8.1.1

Treosulfan

Added link to NICE TA640

6.1.4

Lift Glucose Shot 60ml for mild hypoglycaemia in type 1 diabetes

Added as AMBER SR drug

6.6.2.2

Denosumab 60mg (Prolia) for osteoporosis

Changed from AMBER shared care to AMBER SI drug.

4.7.4.2

Topiramate for migraine prophylaxis

Added as a GREEN drug

1.3.3

Sucralfate 1g/5ml oral suspension

Bile reflux and stomal ulceration = AMBER SI. Short term use post Radio Frequency Ablation (RFA) for Barret's Oesophagus and Endoscopic Mucosal Resection (EMR) = RED

4.7.2

Morphine sulphate 100microgram/ml oral solution

Added as a RED drug for use in neonates1.3.

2.3

Flecainide injection

Added as a RED drug

18

Acetic acid 5% solution

Added as a RED drug

1.5.2

Hydrocortisone Colifoam® Foam enema

Deleted from formulary as discontinued

1.7.4

Diltiazem 2% rectal ointment

Added as an AMBER SI drug

13.8.1

Aldara

Changed from AMBER SI to GREEN drug

13.8.1

Solaraze

Changed from AMBER SI to GREEN drug

13.8.1

Efudix

Changed from AMBER SI to GREEN drug

13.8.1

Actikerall® for actinic keratosis

Added as GREEN drug.

6.1.1

Insulins (all types): risk of cutaneous amyloidosis at injection site

Added link to MHRA Drug Safety Update

1.5.3, 10.1.3, and 13.5.3

Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing

Added link to MHRA Drug Safety Update

4.7.2

Transdermal fentanyl patches for non-cancer pain: do not use in opioid-naive patients

Added link to MHRA Drug Safety Update

4.7.2

Opioids: risk of dependence and addiction

Added link to MHRA Drug Safety Update

13.2.1

Emollients and risk of severe and fatal burns: new resources available

Added link to MHRA Drug Safety Update

13.6.2

Isotretinoin (Roaccutane▼): reminder of important risks and precautions

Added link to MHRA Drug Safety Update

10.1.3

Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors

Added link to MHRA Drug Safety Update

6.6.2

Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment

Added link to MHRA Drug Safety Update

4.2.1

Clozapine and other antipsychotics: monitoring blood concentrations for toxicity

Added link to MHRA Drug Safety Update

4.7.4.2

Fremanezumab

Changed from Unclassifed to RED drug